Medexus Pharmaceuticals (MDP) Q2 2025 earnings summary

Executive summary

• Fiscal Q2 2025 revenue was $26.3 million, net income was $0.1 million, and Adjusted EBITDA reached $6.0 million, reflecting financial discipline and operational efficiency.

• Year-to-date revenue totaled $53.6 million, with net income of $2.1 million and Adjusted EBITDA of $12.1 million.

• The company is preparing for a potential FDA approval and commercial launch of treosulfan in the U.S. by the end of January 2025, with investments in personnel and infrastructure underway.

• Product portfolio performance was mixed: Rupall and Metoject showed strong demand growth, while Ixinity and Rasuvo faced headwinds; Gleolan and pipeline products remain strategic priorities.

Financial highlights

• Q2 2025 revenue was $26.3 million, down 13.2% year-over-year, mainly due to lower net sales of Rasuvo and Ixinity.

• Adjusted EBITDA increased to $6.0 million from $5.3 million year-over-year, driven by cost discipline and manufacturing improvements.

• Net income improved to $0.1 million for the quarter and $2.1 million for six months, compared to net losses last year.

• Gross profit was $14.1 million, with a gross margin of 53.7%, consistent with the prior year.

• Operating cash flow was $6.9 million for the quarter.

Outlook and guidance

• FDA decision on treosulfan NDA expected by January 30, 2025, with commercial launch targeted for the first half of 2025.

• If approved, treosulfan could generate over $100 million in annual US revenue within five years.

• Rupall expected to face generic competition in early 2025, but erosion is projected to be gradual due to private reimbursement dynamics.

• Topical terbinafine Health Canada decision expected in fiscal Q4 2025, with commercial launch targeted for the first half of 2025.

• Management expects steady revenues for the remainder of fiscal 2025.